Skip to main content
Premium Trial:

Request an Annual Quote

Richard Eglen, Timothy Mullane, Bernelle Saperstien

Premium
Richard Eglen has left DiscoverX to become vice president and general manager of discovery and research reagents for PerkinElmer’s Life and Analytical Sciences unit, where he will be responsible for developing and executing PerkinElmer’s discovery and research reagents business strategy.
 
Eglen previously held the post of chief scientific officer and executive vice president for research and development at DiscoverX. Prior to his employment at DiscoverX, Eglen served as senior vice president of assays and reagents for LJL Biosystems. He also has held various positions at Roche, including vice president and director of the Center for Biological Research at Roche Bioscience. Eglen earned his PhD in molecular pharmacology from Trent University in the UK.
 
CBA News has also learned that Timothy Mullane has joined DiscoverX as president.
 
Mullane most recently was employed by Hayward, Calif.-based Biolog, where he served as president and CEO. According to the DiscoverX website, Mullane has also held various positions in operations, business development, and sales and marketing management for Boehringer Mannheim, Biotrack, Ciba Corning, Baxter, and American Hospital Supply. Mullane has a BA in microbiology.

ForteBio announced this week that Bernelle Saperstien has joined the company in the newly created position of vice president, manufacturing operations.
 
Saperstein joins ForteBio from Becton Dickinson Immunocytometry Systems, where she led a team responsible for manufacturing and testing reagents for cell analysis. Prior to this, Saperstein was vice president of operations at First Medical, a subsidiary of Sigma Diagnostics. She also has held positions Roche Diagnostics and Merck. Saperstein holds a BS in chemical engineering from Virginia Tech.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.